Cediranib
Lobular Breast Carcinoma
Roswell Park Cancer InstituteSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Lobular Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Royal Marsden NHS Foundation Trust | Phase 2 | B |
Crizotinib Royal Marsden NHS Foundation Trust | Phase 2 | B |
Zoladex Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
EXEMESTANE Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
FFNP University of Wisconsin, Madison | Phase 2 | CCC |
17-beta-estradiol Università Vita-Salute San Raffaele | Phase 2 | CCC |
Arimidex Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
AE-BROCCOLI Roswell Park Cancer Institute | Early Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →